Repligen (RGEN) Q4 FY25 earnings call

Repligen concluded FY25 with strong organic growth and margin expansion, driven by portfolio diversity and strategic execution. The company issued prudent FY26 guidance, balancing a strengthening macro backdrop with near-term uncertainties around FDA policy and biopharma CapEx decisions, while prioritizing continued investment and M&A. Innovation and operational fitness remain key strategic pillars for future growth.